Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody-targeted thrombolytic agents.

E Haber1, T Quertermous, G R Matsueda

  • 1Cardiac Unit, Massachusetts General Hospital, Boston 02114.

Japanese Circulation Journal
|April 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Usability and feasibility of E-nergEYEze: a blended vision-specific E-health based cognitive behavioral therapy and self-management intervention to reduce fatigue in adults with visual impairment.

BMC health services research·2023
Same author

Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria.

West African journal of medicine·2023
Same author

The effectiveness of motivational interviewing on adherence to wearing orthopedic shoes in people with diabetes at low-to-high risk of foot ulceration: A multicenter cluster-randomized controlled trial.

Diabetes research and clinical practice·2023
Same author

Attitudes and experiences towards the application of motivational interviewing by podiatrists working with people with diabetes at high-risk of developing foot ulcers: a mixed-methods study.

Journal of foot and ankle research·2022
Same author

Using motivational interviewing combined with digital shoe-fitting to improve adherence to wearing orthopedic shoes in people with diabetes at risk of foot ulceration: study protocol for a cluster-randomized controlled trial.

Trials·2021
Same author

Pro- and anti-inflammatory macrophages express a sub-type specific purinergic receptor profile.

Purinergic signalling·2021
Same journal

Vasospastic total occlusion at the left main tract in a single coronary artery.

Japanese circulation journal·2002
Same journal

Spontaneous onset of torsade de pointes in long-QT syndrome and the role of sympathovagal imbalance.

Japanese circulation journal·2002
Same journal

'No-Touch' isolation procedure for ruptured mycotic abdominal aortic aneurysm.

Japanese circulation journal·2002
Same journal

Th1/Th2 balance alteration in the clinical course of a patient with acute viral myocarditis.

Japanese circulation journal·2002
Same journal

Vagal stimulation prior to atrial rapid pacing protects the atrium from electrical remodeling in anesthetized dogs.

Japanese circulation journal·2002
Same journal

Differences in the expression of protein kinase C isoforms and its translocation after stimulation with phorbol ester between young-adult and middle-aged ventricular cardiomyocytes isolated from Fischer 344 rats.

Japanese circulation journal·2002
See all related articles

Plasminogen activator therapy is standard for heart attacks but causes bleeding. New research uses immunology and protein engineering to create safer, more effective treatments for acute myocardial infarction.

Area of Science:

  • Cardiovascular Medicine
  • Biotechnology
  • Immunology

Background:

  • Plasminogen activator therapy is a cornerstone treatment for acute myocardial infarction (heart attack).
  • Current plasminogen activators are limited by significant bleeding complications.
  • There is a critical need for improved therapeutic agents with enhanced safety profiles.

Purpose of the Study:

  • To review the application of advanced biotechnological tools in developing novel plasminogen activators.
  • To explore strategies for creating safer and more effective treatments for acute myocardial infarction.
  • To highlight the role of immunology, molecular biology, and protein engineering in this field.

Main Methods:

  • Review of current literature on plasminogen activator development.

Related Experiment Videos

  • Analysis of immunological approaches to modulate fibrinolysis.
  • Examination of protein engineering techniques for modifying plasminogen activator properties.

    • Main Results:

    • Emerging plasminogen activators show potential for reduced bleeding risk.
    • Molecular engineering allows for targeted delivery and improved efficacy.
    • Immunological insights are guiding the design of next-generation therapies.

    Conclusions:

    • Advancements in immunology, molecular biology, and protein engineering are paving the way for safer plasminogen activators.
    • These innovative approaches promise to improve outcomes for patients with acute myocardial infarction.
    • Future research will focus on clinical translation of these next-generation therapies.